461432-26-8 | (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$17.00	$12.00
1g	98%	in stock	$104.00	$73.00
5g	98%	in stock	$332.00	$232.00
10g	98%	in stock	$605.00	$423.00
25g	98%	in stock	$1,024.00	$717.00
100g	98%	in stock	$2,625.00	$1,837.00

Description

• Catalog Number: AB52027
• Chemical Name: (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS Number: 461432-26-8
• Molecular Formula: C21H25ClO6
• Molecular Weight: 408.8726
• MDL Number: MFCD13182359
• SMILES: CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O

Computed Properties

• Complexity: 472
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 6
• XLogP3: 2.3

Literature

• SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.

  Toxicology and applied pharmacology 20171015

• Pharmacological aspects of the safety of gliflozins.

  Pharmacological research 20170401

• Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

  Clinical pharmacokinetics 20150701

• Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

  Clinical pharmacokinetics 20140101

• Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

  Diabetes, obesity & metabolism 20121101

• Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

  Diabetes, obesity & metabolism 20121001

• Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20120913

• Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.

  European journal of medicinal chemistry 20120901

• Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

  Diabetes 20120901

• Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.

  Obesity (Silver Spring, Md.) 20120801

• Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

  Diabetes care 20120701

• C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry 20120701

• Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

  Postgraduate medicine 20120701

• A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

  Annals of medicine 20120601

• [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].

  Yao xue xue bao = Acta pharmaceutica Sinica 20120601

• [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].

  Orvosi hetilap 20120506

• Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.

  International journal of clinical practice 20120501

• Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.

  Expert opinion on therapeutic patents 20120501

• SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.

  Journal of clinical pharmacology 20120401

• Dapagliflozin for the treatment of type 2 diabetes.

  The Annals of pharmacotherapy 20120401

• Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

  Annals of internal medicine 20120320

• Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study.

  Annals of internal medicine 20120320

• Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.

  Annals of internal medicine 20120320

• Stereoselective C-glycosylation reactions with arylzinc reagents.

  Organic letters 20120316

• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  The Journal of clinical endocrinology and metabolism 20120301

• FDA rejects novel diabetes drug over safety fears.

  Lancet (London, England) 20120211

• Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.

  Advances in therapy 20120201

• Structural selectivity of human SGLT inhibitors.

  American journal of physiology. Cell physiology 20120115

• Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.

  American journal of physiology. Regulatory, integrative and comparative physiology 20120101

• Facile synthesis of 1,2,3-triazole analogs of SGLT2 inhibitors by 'click chemistry'.

  Bioorganic & medicinal chemistry letters 20120101

• Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.

  PloS one 20120101

• Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

  Pharmacotherapy 20120101

• Red carpeting the newer antidiabetics.

  Journal of pharmacology & pharmacotherapeutics 20120101

• The management of type 2 diabetic patients with hypoglycaemic agents.

  ISRN endocrinology 20120101

• Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.

  Core evidence 20120101

• Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

  BMJ open 20120101

• Drugs in traffic: the road to approval.

  Nature medicine 20111206

• Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

  The AAPS journal 20111201

• The role of visfatin in diabetic nephropathy.

  Chonnam medical journal 20111201

• Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

  Clinical therapeutics 20111101

• Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

  Expert review of clinical pharmacology 20111101

• Dapagliflozin--redefining treatment of T2DM?

  Nature reviews. Endocrinology 20111011

• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

  Diabetes, obesity & metabolism 20111001

• Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.

  Bioorganic & medicinal chemistry 20111001

• Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.

  Bioorganic & medicinal chemistry 20110915

• Kidney in diabetes: from organ damage target to therapeutic target.

  Current drug metabolism 20110901

• Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

  Diabetes care 20110901

• Challenges for the treatment of diabetes mellitus.

  Recent patents on endocrine, metabolic & immune drug discovery 20110901

• Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].

  Revue medicale suisse 20110831

• Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.

  Diabetes, obesity & metabolism 20110801

• Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.

  European journal of medicinal chemistry 20110701

• A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.

  Postgraduate medicine 20110701

• Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.

  Bioorganic & medicinal chemistry letters 20110615

• Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors.

  Bioorganic & medicinal chemistry letters 20110615

• New diabetes drugs go beyond insulin to flush out excess sugar.

  Nature medicine 20110601

• Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.

  Journal of medicinal chemistry 20110428

• Discovery of non-glucoside SGLT2 inhibitors.

  Bioorganic & medicinal chemistry letters 20110415

• Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20110401

• Learning from glycosuria.

  Diabetes 20110301

• SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

  Diabetes 20110301

• Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

  Kidney international. Supplement 20110301

• A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.

  Discovery medicine 20110301

• Type 2 diabetes: uses of thiazolidinediones and insulin.

  Diabetes care 20110201

• Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.

  Bioorganic & medicinal chemistry letters 20110115

• Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.

  Journal of medicinal chemistry 20110113

• Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

  Diabetes, obesity & metabolism 20110101

• Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics.

  Current topics in medicinal chemistry 20110101

• Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

  Indian journal of nephrology 20110101

• Management of diabetes across the course of disease: minimizing obesity-associated complications.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• SGLT-2 inhibitors in development for type 2 diabetes treatment.

  The review of diabetic studies : RDS 20110101

• Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.

  Bioorganic & medicinal chemistry letters 20101201

• Dapagliflozin: more than just another oral glucose-lowering agent?

  Expert opinion on investigational drugs 20101201

• Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma.

  Bioanalysis 20101201

• [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].

  Sheng li ke xue jin zhan [Progress in physiology] 20101201

• Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

• Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

• A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.

  North American journal of medical sciences 20101201

• The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.

  Diabetes, obesity & metabolism 20101101

• Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

  Diabetes care 20101001

• Diabetes: Dapagliflozin: an insulin-independent, therapeutic option for type 2 diabetes mellitus.

  Nature reviews. Endocrinology 20101001

• Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

  Current opinion in nephrology and hypertension 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.

  Bioorganic & medicinal chemistry 20100815

• (5-Bromo-2-methyl-phen-yl)(4-eth-oxy-phen-yl)methanone.

  Acta crystallographica. Section E, Structure reports online 20100801

• Dapagliflozin, an SGLT2 inhibitor, for diabetes.

  Lancet (London, England) 20100626

• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20100626

• ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.

  Bioorganic & medicinal chemistry 20100615

• Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.

  Bioorganic & medicinal chemistry letters 20100601

• Neuropathy, retinopathy, and glucose-lowering treatments.

  Diabetes care 20100601

• Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.

  Diabetes, obesity & metabolism 20100601

• Dapagliflozin: BMS 512148; BMS-512148.

  Drugs in R&D 20100501

• (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.

  Journal of medicinal chemistry 20100422

• Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.

  Bioorganic & medicinal chemistry 20100315

• Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

  Drugs 20100305

• In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20100301

• C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.

  Bioorganic & medicinal chemistry letters 20100301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101

• Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.

  Bioorganic & medicinal chemistry letters 20091215

• Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

  IDrugs : the investigational drugs journal 20091201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091201

• (5-Bromo-2-chloro-phen-yl)(4-ethoxy-phen-yl)methanone.

  Acta crystallographica. Section E, Structure reports online 20091201

• Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20091022

• O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.

  Bioorganic & medicinal chemistry letters 20091001

• Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

  Expert opinion on pharmacotherapy 20091001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091001

• A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

  Diabetes care 20090901

• Dapagliflozin for the treatment of type 2 diabetes.

  The Annals of pharmacotherapy 20090701

• Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

  Kidney international 20090601

• Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

  Clinical pharmacology and therapeutics 20090501

• Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

  Clinical pharmacology and therapeutics 20090501

• Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

  Journal of medicinal chemistry 20090409

• Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

  Diabetes care 20090401

• Dapagliflozin: an emerging treatment option in type 2 diabetes.

  Expert opinion on investigational drugs 20090301

• Diabetes treatment.

  Diabetes care 20090301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090301

• Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

  Diabetes, obesity & metabolism 20090201

• Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901

• Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

  International journal of clinical practice 20080801

• Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

  Diabetes 20080601

• Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20080313

• Molecule of the month. Dapagliflozin.

  Drug news & perspectives 20071201